PAH News

January 16, 2019January 16, 2019

Tracleer May Be More Cost-effective Than Some Other PAH Therapies, Review Study Reports

News, PAH News

Treatment of pulmonary arterial hypertension (PAH) with Tracleer (bosentan) may be more cost-effective than epoprostenol medications or palliative care, but less than Revatio (sildenafil) and other endothelin receptor blockers, ... Read more

January 14, 2019January 17, 2019

β-thalassemia Patients at Risk for PAH Show Improvements on Tracleer, Case Report Says

News, PAH News

Tracleer (bosentan) treatment improves mean pulmonary arterial pressure (mPAP) in β-thalassemia patients with potential pulmonary arterial hypertension (PAH), according to a case report of three patients. The report, “The ... Read more

January 11, 2019January 14, 2019

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

CTEPH News, News, PAH News

Long-term treatment with Adempas (riociguat) can reduce right heart size and improve the heart’s pumping function in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), ... Read more

January 7, 2019January 7, 2019

Repeated Measurements of Biomarkers May Improve Prognostic Accuracy in PAH-CHD Patients, Study Finds

News, PAH News

Repeated measurements of different biomarkers over time offer a better risk prediction than single measurements for pulmonary arterial hypertension (PAH) associated with congenital heart disease, a study reports. The ... Read more

January 2, 2019January 15, 2019

Morphogen-IX Raises $23.2 Million to Develop PAH Therapy Candidate MGX292

News, PAH News

Biotechnology company Morphogen-IX has raised $23.2 million to advance development of its lead drug candidate, MGX292, for the treatment of pulmonary arterial hypertension (PAH). The investment, led by Medicxi with contributions ... Read more

December 19, 2018January 8, 2019

Anxiety and Depression in PAH Patients Could Be Eased with Psychosocial Therapies, Review Study Suggests

News, PAH News

Non-pharmacological approaches such as relaxation training, slow breathing, and cognitive behavioral therapy could help lessen anxiety and depression in patients with pulmonary arterial hypertension (PAH), according to a review ... Read more

December 14, 2018January 3, 2019

Study Links Certain High-density Lipoproteins, Better Survival in PAH Patients

News, PAH News

Higher levels of certain high-density lipoproteins (HDLs) improve the survival of pulmonary arterial hypertension (PAH) patients, according to a recent evaluation of two PAH patient cohorts. Targeting certain HDL ... Read more

December 12, 2018January 3, 2019

Genetic Variants Near Two Genes Linked to PAH Risk, Large Study Reports

News, PAH News

Genetic variants close to the SOX17 and the HLA-DPB1 genes are linked to pulmonary arterial hypertension (PAH), according to the findings of the largest genetic study to date in PAH patients. The ... Read more

December 7, 2018December 7, 2018

Switching from Tyvaso to Uptravi Safe, Convenient for PAH Patients, Phase 3b Study Finds

News, PAH News

Switching treatment from United Therapeutics’ Tyvaso (inhaled treprostinil) to Actelion’s Uptravi (oral selexipag) is safe and considered convenient by patients with pulmonary arterial hypertension (PAH), a Phase 3b study reports. ... Read more

PAH News

Tracleer May Be More Cost-effective Than Some Other PAH Therapies, Review Study Reports

β-thalassemia Patients at Risk for PAH Show Improvements on Tracleer, Case Report Says

Long-term Adempas Treatment May Reverse Right Heart Deficits in Patients with PAH, CTEPH, Study Finds

Repeated Measurements of Biomarkers May Improve Prognostic Accuracy in PAH-CHD Patients, Study Finds

Top 10 Pulmonary Hypertension Stories of 2018

Morphogen-IX Raises $23.2 Million to Develop PAH Therapy Candidate MGX292

Anxiety and Depression in PAH Patients Could Be Eased with Psychosocial Therapies, Review Study Suggests

Study Links Certain High-density Lipoproteins, Better Survival in PAH Patients

Genetic Variants Near Two Genes Linked to PAH Risk, Large Study Reports

Switching from Tyvaso to Uptravi Safe, Convenient for PAH Patients, Phase 3b Study Finds

Pin It on Pinterest